[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR20130288A - COMPRESSED PHARMACEUTICAL CONTROLLED RELEASE FOR ORAL ADMINISTRATION - Google Patents

COMPRESSED PHARMACEUTICAL CONTROLLED RELEASE FOR ORAL ADMINISTRATION

Info

Publication number
CR20130288A
CR20130288A CR20130288A CR20130288A CR20130288A CR 20130288 A CR20130288 A CR 20130288A CR 20130288 A CR20130288 A CR 20130288A CR 20130288 A CR20130288 A CR 20130288A CR 20130288 A CR20130288 A CR 20130288A
Authority
CR
Costa Rica
Prior art keywords
oral administration
controlled release
compressed pharmaceutical
pharmaceutical controlled
compressed
Prior art date
Application number
CR20130288A
Other languages
Spanish (es)
Inventor
Arroyo Héctor Senosiain
Paniagua María Angélica Arzola
Hernández Gustavo Barranco
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46245166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130288(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of CR20130288A publication Critical patent/CR20130288A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN TIENE SU APLICACIÓN EN EL CAMPO FARMACÉUTICO, ESPECIALMENTE EN EL DE COMBINACIÓN Y COMPOSICIÓN FARMACÉUTICAS QUE COMPRENDEN UN INHIBIDOR DE LA LIPASA Y UNA FITOALEXINA Y VEHICULOS O EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES.-THE PRESENT INVENTION HAS ITS APPLICATION IN THE PHARMACEUTICAL FIELD, ESPECIALLY IN THE PHARMACEUTICAL COMBINATION AND COMPOSITION THAT INCLUDES A LIPASE INHIBITOR AND A PHYTOALEXINE AND PHARMACEUTICALLY ACCEPTABLE VEHICLES.-

CR20130288A 2010-12-17 2013-06-13 COMPRESSED PHARMACEUTICAL CONTROLLED RELEASE FOR ORAL ADMINISTRATION CR20130288A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2010014153A MX2010014153A (en) 2010-12-17 2010-12-17 Controlled-release pharmaceutical tablet for oral administration.
PCT/IB2011/055720 WO2012080984A2 (en) 2010-12-17 2011-12-16 Controlled-release pharmaceutical tablet for oral administration

Publications (1)

Publication Number Publication Date
CR20130288A true CR20130288A (en) 2013-08-13

Family

ID=46245166

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130288A CR20130288A (en) 2010-12-17 2013-06-13 COMPRESSED PHARMACEUTICAL CONTROLLED RELEASE FOR ORAL ADMINISTRATION

Country Status (11)

Country Link
BR (1) BR112013014963A2 (en)
CL (1) CL2013001707A1 (en)
CO (1) CO6721021A2 (en)
CR (1) CR20130288A (en)
DO (1) DOP2013000136A (en)
EC (1) ECSP13012766A (en)
GT (1) GT201300154A (en)
MX (1) MX2010014153A (en)
PE (1) PE20140675A1 (en)
RU (1) RU2603469C2 (en)
WO (1) WO2012080984A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016058813A1 (en) 2014-10-16 2016-04-21 Koninklijke Philips N.V. Aligning a patient within an mr scanner

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
JP2005516020A (en) * 2001-12-20 2005-06-02 ファルマシア・コーポレーション Zero-order sustained release dosage form and process for its production

Also Published As

Publication number Publication date
PE20140675A1 (en) 2014-06-25
CO6721021A2 (en) 2013-07-31
WO2012080984A2 (en) 2012-06-21
RU2603469C2 (en) 2016-11-27
RU2013127408A (en) 2015-01-27
BR112013014963A2 (en) 2016-09-13
MX2010014153A (en) 2012-06-18
GT201300154A (en) 2014-05-07
WO2012080984A3 (en) 2012-08-16
CL2013001707A1 (en) 2014-01-10
ECSP13012766A (en) 2013-09-30
DOP2013000136A (en) 2013-10-15

Similar Documents

Publication Publication Date Title
CL2015000345A1 (en) Use of a combination for melanoma comprising the administration of cobimetinib and vemurafenib.
CL2013003145A1 (en) Pharmaceutical formulation comprising mixture of anti-alpha4 beta7 antibody, an antioxidant or chelator and at least one free amino acid.
CL2013003313A1 (en) Compounds derived from pharmaceutically acceptable 2,4-diaminoquinazolines, salts or solvates; pharmaceutical composition comprising them; and use in the treatment of a disorder involving the modulation of tlr7 and / or tlr8.
CL2012003281A1 (en) Use of specific sgc stimulating and / or activating compounds; pharmaceutical formulation comprising said compounds; kit comprising the compounds, and use for the prevention and / or treatment of systematic sclerosis.
CL2011000214A1 (en) Pharmaceutical composition comprising micronized progesterone and type II safflower oil; and use for the treatment of a condition related to insufficient progesterone secretion.
CR20110110A (en) PHARMACEUTICAL COMPOSITION
CL2013003577A1 (en) Use of a pharmaceutical composition comprising panobinostat and ruxolitinib in the prevention and / or treatment of myeloproliferative neoplasms.
CR20120008A (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
GT201200304A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE HYDROMORPHONE AND NALOXONE
UY33530A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES
BR112014021068A8 (en) inhibitor of an interaction between phosphatidylserine and a thymic receptor, pharmaceutical composition and use of an inhibitor
CL2009001841A1 (en) Use of a sustained release composition of 4-aminopyridine to prepare a medicament useful for treating multiple sclerosis in a subject.
UY34931A (en) ? COMPOSITE FORMULATION FOR ORAL ADMINISTRATION THAT INCLUDES METFORMIN AND ROSUVASTATIN ?.
CL2012003265A1 (en) Tamarind seed polysaccharide for use in the treatment of infectious diseases; pharmaceutical and / or anti-inflammatory dermocosmetic composition containing said polysaccharide; use of a tamarind seed polysaccharide.
RS52461B (en) Flupentixol compositions
SV2010003753A (en) DRONEDARONA FOR THE PREVENTION OF CARDIOVERSION
CL2013000335A1 (en) Highly crystalline form of valsartan; process to prepare it; pharmaceutical composition that understands it and use in the treatment of hypertension.
ECSP15050273A (en) ORAL FORMULATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
MX343409B (en) Pharmaceutical combinations including anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders.
CR20130288A (en) COMPRESSED PHARMACEUTICAL CONTROLLED RELEASE FOR ORAL ADMINISTRATION
CL2012003661A1 (en) Pharmaceutical sustained release composition comprising a compound derived from 2-phenylthiazole; and use in the treatment or prevention of hypertension or normal high blood pressure.
ES2422877B1 (en) COMBINATION AND COMPOSITION FOR OBESITY TREATMENT
AR067351A1 (en) PICOTAMIDE COMBINATION WITH NAFRONIL
ECSP13012765A (en) COMBINATION AND COMPOSITION FOR OBESITY TREATMENT
MY161769A (en) Pharmaceutical composition for treating hcv infections